Louisiana State Employees Retirement System Has $6.98 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Louisiana State Employees Retirement System trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,300 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Louisiana State Employees Retirement System’s holdings in Regeneron Pharmaceuticals were worth $6,982,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Nuveen LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $343,764,000. Pacer Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after acquiring an additional 390,374 shares during the period. Assenagon Asset Management S.A. raised its holdings in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock worth $305,311,000 after purchasing an additional 303,785 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after purchasing an additional 174,056 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after purchasing an additional 121,545 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ REGN opened at $583.24 on Wednesday. The company’s fifty day simple moving average is $573.16 and its 200 day simple moving average is $566.16. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,024.36. The firm has a market cap of $61.82 billion, a PE ratio of 14.70, a P/E/G ratio of 1.87 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the business earned $11.56 earnings per share. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Finally, Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.